C07J 11/00
Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position
Official title: Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 3
C07J11/00 (Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position) appears on 80 US grants and 59 published applications in this corpus.
Search patents in C07J- Granted patents
- 80
- Published applications
- 59
- Assignees
- 57
- Inventors
- 210
- Latest grant
- 19 Aug 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 1 | 0 |
| 1977 | 0 | 0 |
| 1978 | 3 | 0 |
| 1979 | 2 | 0 |
| 1980 | 2 | 0 |
| 1981 | 3 | 0 |
| 1982 | 0 | 0 |
| 1983 | 2 | 0 |
| 1984 | 1 | 0 |
| 1985 | 1 | 0 |
| 1986 | 0 | 0 |
| 1987 | 0 | 0 |
| 1988 | 0 | 0 |
| 1989 | 3 | 0 |
| 1990 | 4 | 0 |
| 1991 | 1 | 0 |
| 1992 | 4 | 0 |
| 1993 | 2 | 0 |
| 1994 | 2 | 0 |
| 1995 | 1 | 0 |
| 1996 | 0 | 0 |
| 1997 | 5 | 0 |
| 1998 | 8 | 0 |
| 1999 | 1 | 0 |
| 2000 | 2 | 0 |
| 2001 | 2 | 0 |
| 2002 | 0 | 0 |
| 2003 | 0 | 0 |
| 2004 | 0 | 4 |
| 2005 | 0 | 3 |
| 2006 | 0 | 0 |
| 2007 | 1 | 1 |
| 2008 | 0 | 0 |
| 2009 | 1 | 0 |
| 2010 | 1 | 0 |
| 2011 | 0 | 1 |
| 2012 | 0 | 2 |
| 2013 | 0 | 3 |
| 2014 | 0 | 2 |
| 2015 | 0 | 3 |
| 2016 | 2 | 3 |
| 2017 | 0 | 4 |
| 2018 | 3 | 1 |
| 2019 | 3 | 9 |
| 2020 | 4 | 6 |
| 2021 | 4 | 4 |
| 2022 | 5 | 6 |
| 2023 | 2 | 3 |
| 2024 | 1 | 2 |
| 2025 | 3 | 2 |
By publication year. Applications have been published since 2001.
Recent patents
- Steroids and methods of manufacture19 Aug 2025US 12,391,723 B2Trustees of Dartmouth College
- Intermediates for the preparation of 11-methylene steroids18 Feb 2025US 12,227,537 B2Crystal Pharma, S.A.U.
- Process for preparing high puritiy allopregnanolone and intermediates thereof28 Jan 2025US 12,209,107 B2Crystal Pharma, S.A.U.
- Compositions and methods for treating CNS disorders20 Aug 2024US 12,065,463 B2Sage Therapeutics, Inc.
- Neuroactive steroids and compositions thereof9 May 2023US 11,643,434 B2Sage Therapeutics, Inc.
- Neuroactive steroids and compositions thereof7 Aug 2025US 2025/0250296 A1Sage Therapeutics, Inc.
- Neuroactive steroids and compositions thereof24 Jul 2025US 2025/0236639 A1Sage Therapeutics, Inc.
- Compositions and methods for treating cns disorders7 Nov 2024US 2024/0368213 A1Sage Therapeutics, Inc.
- Neuroactive steroids and compositions thereof22 Aug 2024US 2024/0279268 A1Sage Therapeutics, Inc.
- Neuroactive steroids and compositions thereof10 Aug 2023US 2023/0250128 A1Sage Therapeutics, Inc.
Most cited
By later US patents
- 4-Aza-17.beta.-substituted-5.alpha.-androstan-3-one-reductase inhibitors159US 4,377,584 AMerck & Co., Inc. · 1983
- Methods for controlling ocular hypertension with angiostatic steroids86US 4,876,250 AAlcon Laboratories, Inc. · 1989
- Angiostatic steroids and methods and compositions for controlling ocular hypertension78US 5,371,078 AAlcon Laboratories, Inc. · 1994
- Use of angiostatic steroids in photodynamic therapy75US 6,297,228 B1Alcon Manufacturing, Ltd. · 2001
- Angiostatic agents and methods and compositions for controlling ocular hypertension73US 5,990,099 AAlcon Laboratories, Inc. · 1999